{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:45:09Z","timestamp":1793810709619,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004505","name":"Universit\u00e0 degli Studi di Catania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejogrb.2021.06.009","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:57:17Z","timestamp":1623459437000},"page":"67-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Intravaginal 6.5\u00a0mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study"],"prefix":"10.1016","volume":"263","author":[{"given":"Maria Grazia","family":"Matarazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sarpietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-7894","authenticated-orcid":false,"given":"Debora","family":"Fiorito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Di Pasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Ingrassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Marzio","family":"Panella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-0932","authenticated-orcid":false,"given":"Salvatore","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2021.06.009_b0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0015","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0020","doi-asserted-by":"crossref","unstructured":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society, Menopause: September 2020 - Volume 27 - Issue 9 - p 976-992","DOI":"10.1097\/GME.0000000000001609"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0025","doi-asserted-by":"crossref","unstructured":"Latthe P, Middleton L, Rachaneni S et al. On behalf of the BUS Collaborative Group. Ultrasound bladder wall thickness and detrusor overactivity: a multicentre test accuracy study. 2017 Royal College of Obstetricians and Gynaecologists.","DOI":"10.1111\/1471-0528.14503"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/iju.12298","article-title":"Factors influencing patient satisfaction with antimuscarinics treatment of overactive bladder syndrome: results of real-life clinical study","volume":"21","author":"Akino","year":"2014","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.ejogrb.2021.06.009_b0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol."},{"issue":"1","key":"10.1016\/j.ejogrb.2021.06.009_b0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/nau.20090","article-title":"Botulinum toxin for the treatment of lower urinary tract symptoms: a review","volume":"24","author":"Sahai","year":"2005","journal-title":"Neurourol Urodyn."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0045","unstructured":"Intrarosa, DHEA intravaginal (prasterone, intravaginal) dosing, indi- cations, interactions, adverse effects, and more. Published March 12, 2018."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0050","unstructured":"European Medicines Agency. Intrarosa: summary of product characteristics. 2019."},{"issue":"4 Suppl 1","key":"10.1016\/j.ejogrb.2021.06.009_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0090-4295(03)00676-9","article-title":"The role of estrogens in female lower urinary tract dysfunction","volume":"62","author":"Robinson","year":"2003","journal-title":"Urology."},{"issue":"11","key":"10.1016\/j.ejogrb.2021.06.009_b0060","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/00016340701625446","article-title":"Pelvic floor sex steroid hormone receptors, distribu tion and expression in pre- and postmenopausal stress urinary in- continent women","volume":"86","author":"S\u00f6derberg","year":"2007","journal-title":"Acta Obstet Gynecol Scand."},{"issue":"4","key":"10.1016\/j.ejogrb.2021.06.009_b0065","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.sxmr.2018.03.005","article-title":"Role of Androgens in Female Genitourinary Tissue Structure and Function: Implications in the Genitourinary Syndrome of Menopause","volume":"6","author":"Traish","year":"2018","journal-title":"Sex Med Rev."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.maturitas.2011.06.005","article-title":"Vaginal DHEA to treat menopause related atrophy: a review of the evidence","volume":"70","author":"Panjari","year":"2011","journal-title":"Maturitas."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0075","doi-asserted-by":"crossref","DOI":"10.1080\/14656566.2019.1703951","article-title":"Goldstein AT : An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause","author":"Holton","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"5\u20136","key":"10.1016\/j.ejogrb.2021.06.009_b0080","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0039-128X(98)00007-5","article-title":"DHEA and the intracrine formation of androgens and estrogen\u2019s in peripheral target tissues: its role during aging","volume":"63","author":"Labrie","year":"1998","journal-title":"Steroids"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/frne.2001.0216","article-title":"DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology","volume":"22","author":"Labrie","year":"2001","journal-title":"Front Neuroendocrinol."},{"issue":"2","key":"10.1016\/j.ejogrb.2021.06.009_b0090","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/GME.0000000000001177","article-title":"Intracrinology and menopause: the science describing the cell-specifc intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues","volume":"26","author":"Labrie","year":"2019","journal-title":"Menopause."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0095","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jsbmb.2016.03.016","article-title":"Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks","volume":"159","author":"Martel","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"10.1016\/j.ejogrb.2021.06.009_b0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/GME.0000000000000571","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) onmoderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause","volume":"23","author":"Labrie","year":"2016","journal-title":"Menopause."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0105","first-page":"1","article-title":"Comparison of Intravaginal 6.5mg (0.50%) Prasterone, 0.3mg Conjugated Estrogens and 10\u03bcg Estradiol on Symptoms of Vulvovaginal Atrophy. Steroid Biochem","volume":"174","author":"Archer","year":"2017","journal-title":"Mol Biol."},{"issue":"6","key":"10.1016\/j.ejogrb.2021.06.009_b0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/GME.0000000000000808","article-title":"Science of intracrinology in postmenopausal women","volume":"24","author":"Labrie","year":"2017","journal-title":"Menopause."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0115","doi-asserted-by":"crossref","DOI":"10.1097\/gme.0b013e31819e8e2d","article-title":"Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy","author":"Labrie","year":"2009","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.ejogrb.2021.06.009_b0120","first-page":"116","article-title":"Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function","volume":"18","author":"La Rosa","year":"2019","journal-title":"Prz Menopauzalny."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1464-410X.2006.05885.x","article-title":"Italian validation of the International Consultation on Incontinence Questionnaires","volume":"97","author":"Tubaro","year":"2006","journal-title":"BJU International"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0130","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/nau.22363","article-title":"Validation of use of the International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI-SF) for impairment rating: A transversal retrospective study of 120 patients","volume":"32","author":"Timmermans","year":"2013","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0135","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/0378-5122(95)00956-6","article-title":"Urogenital ageing: an old problem newly recognized","volume":"22","author":"Bachmann","year":"1995","journal-title":"Maturitas"},{"issue":"11","key":"10.1016\/j.ejogrb.2021.06.009_b0140","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","article-title":"Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: Results from the IQOLA Project","volume":"51","author":"Gandek","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"3 Pt 1","key":"10.1016\/j.ejogrb.2021.06.009_b0145","first-page":"355","article-title":"The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society","volume":"14","author":"North American Menopause Society","year":"2007","journal-title":"Menopause."},{"issue":"2","key":"10.1016\/j.ejogrb.2021.06.009_b0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"2016 IMS recommendations on women\u2019s midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejogrb.2018.01.002","article-title":"Does Vaginal Estriol Make Urodynamic Changes in Women With Overactive Bladder Syndrome and Genitourinary Syndrome of Menopause?","volume":"222","author":"Matarazzo","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/nau.20583","article-title":"Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome","volume":"28","author":"Tseng","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0165","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/SPV.0000000000000256","article-title":"Combined tolterodine and vaginal estradiol cream for overactive bladder symptoms after randomized single-therapy treatment","volume":"22","author":"Ellington","year":"2016","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0170","doi-asserted-by":"crossref","unstructured":"Li B, Duan H, Chang Y, Wang S. Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients..Pharmacol Res. 2021;164:105360. doi: 10.1016\/j.phrs.2020.105360. Epub 2020 Dec 8.","DOI":"10.1016\/j.phrs.2020.105360"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0175","doi-asserted-by":"crossref","unstructured":"Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies. Blanco ZE, Lilue M, Palacios S. Drugs Context. 2020 Jul 1;9:2020-3-6. doi: 10.7573\/dic.2020-3-6. eCollection 2020.","DOI":"10.7573\/dic.2020-3-6"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1185\/03007995.2013.850068","article-title":"Incidence of genitourinary conditions in women with a diagnosis of vulvar\/vaginal atrophy","volume":"30","author":"Constantine","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1258\/136218001100321263","article-title":"The pathophysiology and management of postmenopausal urogenital oestrogen deficiency","volume":"7","author":"Robinson","year":"2001","journal-title":"J Br Menopause Soc"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1754045313511398","article-title":"The effect of hormones on the lower urinary tract","volume":"19","author":"Robinson","year":"2013","journal-title":"Menopause Int"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0195","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40266-019-00700-w","article-title":"Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause","volume":"36","author":"Kagan","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejogrb.2021.06.009_b0200","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/gme.0b013e31819e85c6","article-title":"Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0205","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jsbmb.2008.06.003","article-title":"Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women","volume":"111","author":"Labrie","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"8","key":"10.1016\/j.ejogrb.2021.06.009_b0210","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40266-019-00693-6","article-title":"Prasterone: A Review in Vulvovaginal Atrophy","volume":"36","author":"Heo","year":"2019","journal-title":"Drugs Aging."},{"issue":"1","key":"10.1016\/j.ejogrb.2021.06.009_b0215","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13697137.2011.647840","article-title":"Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.maturitas.2016.06.010","article-title":"The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs","volume":"91","author":"Nappi","year":"2016","journal-title":"Maturitas."},{"key":"10.1016\/j.ejogrb.2021.06.009_b0225","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/jsm.12517","article-title":"Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women","volume":"11","author":"Labrie","year":"2014","journal-title":"J Sex Med"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211521002803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211521002803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:52:22Z","timestamp":1759557142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211521002803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":45,"alternative-id":["S0301211521002803"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2021.06.009","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravaginal 6.5\u00a0mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2021.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}